novo nordisk cagrisema - Search News

Novo Nordisk shares plunge

Reuters on MSN · 1d

Novo Nordisk's new obesity drug trial data disappoints again

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

The Wall Street Journal on MSN · 1d

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.

Yahoo Finance · 1d

Novo Nordisk Shares Tumble 8% on CagriSema Weight Loss Miss

Novo Nordisk (NVO, Financial) shares fell 8% on Monday morning following disappointing Phase 3 trial results for its weight loss drug CagriSema. The Redefine 2 trial

1d

Novo Nordisk: CagriSema Disappoints Again

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

GlobalData on MSN1d

Novo Nordisk’s stock drops despite CagriSema hitting goal of Phase III trial

The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...

1d

Novo Nordisk stock slides Monday on second-generation GLP-1 data

Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...

1d

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68 ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results